SUMMARY -4' ,4" -di(2-im idazolin-2-yl)terephthalanilide dihydrochloride hemihydrate (NSC-35843) and its 2-chloro analogue (NSC-38280) represent a class of imidazolinylterephthalanilides highly active against a number of rodent neoplasms. Drug uptake by sensitive and resistant lines of the ascites and solid forms of L 1210 lymphocytic leukemia has been determined with reference to the time after administration of the drugs to mice bearing 
However, 1/2 hour after drug administration, drug levels were comparable in sensitive and resistant lines, and approximated the 24-hour drug levels in sensitive cells. Experiments in vitro also indicated no significant differences in the initial binding of NSC-38280 to sensitive or resistant ascites L 1210 cells. Several lines of evidence suggested that NSC-38280 was not metabolically altered by L 1210 or P388 cells. With both CU-Iabeled and unlabeled phthalanilide, essentially all the drug added in vitro to L 1210 or P388 ascites cells was recovered chromatographically. The chromatograms of extracts of solid tumors from mice which had received NSC-38280 revealed no drug-related peak other than that of authentic NSC-38280. However, NSC-35843 appeared to undergo a change in vivo that decreased its basicity 1 Received January 31,1964. SEVERAL PHTHALANILIDE DERIVA-TIVES have markedly increased survival of mice bearing lymphocytic leukemias L1210 and P388 and have excited considerable interest as possible agents for the therapy of leukemias (1) . As with other agents (2), resistant lines have been developed 5 (3) . In an effort to elucidate some characteristics of these resistant tumors, the distri~ bution of 2 phthalanilides was investigated in both solid and ascites L1210 and in ascites P388 to determine if differences existed between the sensitive and resistant lines. Binding of 2-chloro~4', 4"-di (2-imidazolin-2-yl) terephthalanilide dihydrochloride (NSC-38280) to ascites L1210 under various conditions in vitro also was examined in an attempt to distinguish between sensitive and re~ sistant lines by the use of this criterion.
MATERIAL AND METHODS
NSC-38280 and 4',4" -di(2-imidazolin-2-yl)-terephthalanilide dihydrochloride hemihydrate (NSC-35843) were supplied by the Cancer Chemotherapy National Service Center, National Insti~ tutes of Health, Bethesda, Maryland.
Tumor lines and animals.-Both solid and ascites forms of the sensitive and resistant lines of L1210 and P388 were carried in BDFl (C57BL/6 9 X DBA/2 d")F 1 hybrid mice by weekly transplants. A 2 mm fragment of the solid tumor was implanted subcutaneously in the axillary region. In delayed therapy experiments, the phthalanilides were ad~ ministered intraperitoneally at 16 mg per kg per day for NSC-38280 and 32 mg per kg per day for NSC-35843. The drugs were suspended in saline with one drop of Tween 80 (polyoxethylene sorbitan mono-oleate) obtained from the Atlas Chemicals Industries, Inc., Wilmington, Delaware, and were subjected to sonic vibration to produce a uniform suspension. The time intervals between the implantation of the tumor and the injection of compounds are reported with the results of the experiments.
Animals bearing the solid tumors were killed either 1 hour or 24 hours after the last injection, and the tumors were excised, weighed, and frozen prior to analysis for phthalanilide. In general, 48 animals constituted an experimental group; 24 were held to determine mean survival time and the survivors from the rest were killed at prescribed times for drug analysis and measurements of average tumor growth.
Ascites~bearing animals were killed; ascitic fluid was withdrawn to oxalated tubes and immediately analyzed for phthalanilide.
Analysis Qj tumors for phthalanilide.-Freshly harvested or frozen solid tumors were homogenized in 1 N levulinic acid and extracted with ethanol (4). The evaporated ethanol extracts were taken up in water and subjected to chromatography on cellulose citrate columns with the elution schemes developed for NSC-38280 and NSC-35843.
Ascitic fluid was diluted with an equal volume of 0.9 percent NaCI and centrifuged at 700 X g for 10 minutes to concentrate the cells. The erythrocytes accompanying L1210 cells were lysed by brief hypotonic shock (30 sec, 0° C) (5) , and the ascites cells were collected by centrifuga~ tion. With the P388 ascites cells from fluid that was not bloody, a second saline wash was substituted for the erthrocyte-removal step. Following a cell count with a hemocytometer, the cells were extracted with levulinic acid and ethanol as described previously (4) . The evaporated ethanol extracts were taken up in water and subjected to chromatography on cellulose citrate columns with the elution schemes developed for NSC-38280 and NSC-35843.
Cellulose citrate (Whatman CT-60) columns were prepared with a slurry made of 0.5 g of the powder poured into a chromatographic column (11 mm inside diameter). The column was washed with 10 to 2( ml of 0.1 N HCl followed by at least 20 ml of water to produce a neutral effluent. The effluent should have zero absorbance at 270 m,u.
Mter the sample had been added to the column, water was added until all levulinic acid and other materials absorbing at 270 m,u had been eluted. Then collection of 3 ml fractions was begun. The first 2 fractions were eluted after the addition of 6 ml of 2 N KCl that served to remove much material absorbing in the 260 to 280 m,u region. The phthalanilides then could be eluted from the column in several ways, depending on the nature of the other material in the extract and the purpose of the experiment. NSG-38280 could be displaced from the column with 0.75 N KG1, 0. Mter elution, the concentration of drug could be determined by measurement of the absorbance at its ultraviolet absorption maximum or by acid hydrolysis and subsequent colorimetric determination of the aromatic amine content (4). The chromatographic method has been verified with C14-labeled NSC-3828b. Binding studies with L1210 ascites cells.-The initial binding experiments were performed with ascites cells obtained by subjection of the ascitic fluid to a brief shock with 2 percent acetic acid (20 ml 2 % acetic acid to 1 ml ascitic fluid) to lyse erythrocytes. The ascites cells were collected by centrifugation, washed once in 0.9 percent saline, and resuspended in a saline solution of NSC-38280 or in a saline solution without drug as a control. At various times, samples were removed and centrifuged at 10,000 X g for 5 minutes. The absorbance of the supernatants was determined at 292 m,u, the absorption maximum of NSC-38280, and at 270 m,u in a Beckman DU spectrophotometer.
A second protocol was also employed. Freshly drawn ascitic fluid was mixed with a dextran-glucose solution (4 % dextran in 3 % glucose) 6 stand at 4 0 C for 2 hours. At the end of this period, most erythrocytes had settled to the bottom of the tube, and the ascites cells remained as a light-pink band above the packed erythrocytes. The ascites cells were withdrawn in the fluid, centrifuged, and washed with 0.9 percent saline. Binding of NSC-38280 to the ascites cells was determined as described.
For the determination of the binding of C14_ labeled NSG-60339 7 to ascites cells in vitro, oxalated ascitic fluid was allowed to stand overnight at 4 0 C. The fluid and pink ascites-cell layer were carefully removed with a Pasteur pipette. Radioactive phthalanilide (100 ,ug) was added to the ascitic fluid-cell mixture (5-6 ml), and samples were removed at various times for analysis. The cells were separated from the supernatant by centrifugation at 10,000 X g for 2 minutes, washed once in 0.9 percent saline, and the wash liquid was combined with the fluid. Samples were taken from the cell and ascitic fluid portions for determination of radioactivity. Both cell and fluid fractions were extracted for chromatographic analysis. Samples of the column eluates were plated in planchets and counted with the use of a thin-window (1.9 mg/cm 2 ) Geiger detector.
RESULTS

Eff~cts of Phthalanilides on Growth of Solid L 1210 and Duration of Survival of Host
The effect of NSC-35843 and NSC-38280 on tumor growth and on length of survival of mice bearing the tumors was determined. The data, summarized in table 1, indicate that, although delayed therapy with either drug prolonged 8 (table 2) . Typical chromatographic separations of NSC-38280 on cellulose citrate are shown in text-figure 1. It was found that 2 N KCl eluted a considerable amount of ultravioletabsorbing material, which may be of nucleotide or nucleic acid origin as is indicated by its peak absorbance at 260 m,u. When the eluant was changed to 0.1 N HCl, the NSC-38280 was eluted from the column in a rather sharp peak. Very little material was obtained from untreated controls with 0.1 N HCl elution.
The phthalanilide concentration in sensitive tumors was determined by chromatographic separation of NSC-38280 after various periods of therapy. The data in table 3 suggest that the drug level in the sensitive tumor tissue increased gradually as a function of the number of doses. However, the uptake of NSC-38280 by the resistant line under these conditions was less than 1 to 3 p.g per g (limit of sensitivity of the analytical method) following 3 injections of NSC-38280, and measurable amounts were found only after the fourth and fifth injections. After treatment with NSC-35843, similar differences in accumulation in solid tumor L1210 were observed (table 2) . However, the sensitive tumor contained two to three times as much of a material that had a similar absorption spectrum compared to the compound administered, but was eluted with 0.75 N KC!. NSC-35843 could not be eluted with 0.75 N KC!, and NSC-35843 added to treated tumor extracts was quantitatively recovered in the fig. 2 ), which indicated that some change had occurred in vivo which decreased the basicity of the molecule and allowed its removal from the column with 0.75 N KC!.
In this connection, an experiment was carried out in which homogenates of both treated and untreated sensitive and resistant tumors were incubated aerobically with either NSC-38280 or NSC-35843 for 90 minutes at 37° C to determine whether any changes could be observed either by direct detection of aromatic amine (8) 
Binding of NSC-38280 to Ascites Cells
Studies in vitro with L1210 ascites cells.-In a preliminary experiment, it was observed that the binding of NSC-38280 to ascites cells, obtained by centrifugation after dilute acetic acid lysis of erythrocytes, was essentially complete in 15 minutes. With this time as a standard incubation period, no difference could be discerned in the binding of the phthalaniIide to either sensitive or resistant cells.
However, the pH of the final incubation mixture was between 4 and 5, so it was not possible to attach physiological significance to these results.
To obviate this difficulty, ascites cells were obtained after the erythrocytes were settled in a dextran-glucose mixture. Again, there was no marked difference in phthalanilide binding between sensitive and resistant cells (text- fig. 3 ). The total amount of drug bound was about 6 p,g per 10 8 cells.
To provide a more physiological medium for the binding studies in vitro, the ascites cells were suspended in ascitic fluid rather than saline. NSC-60339 (the free base of NSC-38280) labeled with C14 was used to follow the binding of phthalanilide to the ascites cells. Binding of C14 label as a function of time in 2 separate experiments is shown in text-figure 4. After 15 minutes' incubation, most of the binding had occurred. In the subsequent 45 minutes, little additional binding took place, and in one case involving sensitive cells the actual amount of bound radioactivity decreased, possibly due to cell lysis. The amount of drug bound per ..,.
-0 Chromatograms of the cell extracts measuring the ultraviolet absorbance and radioactivity of the eluted fractions corresponded remarkably well. This indicated that the intact drug molecule was recovered (text- fig. 5 ).
Studies in vivo.-The uptake of NSC-38280 by sensitive and resistant lines of the ascites form of L1210 and P388 was determined at ~ hour and 24 hours after a single intraperitoneal dose of the phthalanilide was administered to the host mice. Mter ~-hour exposure, the drug levels were similar in sensitive and resistant lines of both tumors (table 4) . After 24 hours, however, the sensitive cells maintained drug levels comparable to the ~-hour values, while the resistant cells lost, in some cases, as much as 90 percent of the drug bound after the first }f hour of exposure. This decrease in resistant cells was neither a function of increased proliferation of resistant cells nor a result of the production of a larger quantity of ascitic fluid, since no differences were found in cell numbers or volume of ascitic fluid. Furthermore, the reduction in drug level did not appear to be due to metabolic alteration of the phthalanilide by the ascites cells. After incubation of NSC-38280 with sensitive or resistant P388 cells for 90 minutes in vitro, the drug was quantitatively recovered from the incubation mixtures by column chromatography.
I t was not possible to distinguish between intracellular and extracellular binding by differential centrifugation, but preliminary intracellular distribution experiments indicated that NSC-38280 is distributed equally between mitochondrial and nuclear pellets after differential centrifugation, and that less than 10 percent is found in the microsomal and supernatant fractions. Other preliminary studies with tritiated NSC-38280 revealed drug in the nucleus and cytoplasm }f hour and 24 hours after drug was administered to host mice; there was no evidence of localization of drug on the outside of cells.
DISCUSSION
The increased accumulation of NSC-38280 In vivo by the sensitive lines of both solid and ascites L1210 and in ascites P388 as compared to the resistant lines suggests the existence of different mechanisms in the sensitive and resistant tumors for transport, binding, or metabolism of the phthalanilide, or perhaps a combination of these functions. The binding studies in vitro do not help to explain the increased accumulation found in vivo, since the binding in vitro of phthalanilide to sensitive and resistant tumor cells isolated by several methods showed no marked variation between cell lines. Jacquez and Hutchinson (9) reported that, in studies in vitro carried out with azaserine and ascites L121O, the uptake of drug was similar in sensitive and resistant lines, and, in approximately 10 minutes, the binding of drug was complete. With 6-diazo-5-oxo-norleucine (DON) in the same system, the sensitive line accumulated only slightly less than the resistant cells. Since no data were given for the accumulation of these compounds in vivo, it is not possible to compare the results obtained with DON and azaserine to the phthalanilide data in vivo. However, all 3 compounds (NSC-38280, azaserine, and DON), which are weak nitrogen-containing bases, behave similarly in an environment in vitro. Perhaps the rapid binding of these compounds is a function of adsorption or attachment to the outer surface of the tumor cell and may not represent an actual uptake into the cell, and the differences observed in vivo in sensitive and resistant cells may be due to differences in permeability.
The disposition studies (10), as well as those reported in this paper, suggest that NSC-38280 maintains its molecular integrity in vivo. A preliminary study showed that homogenates from sensitive and resistant solid tumors or suspensions of ascites cells did not alter either NSC-38280 or NSC-35843. However, the presence of a possible metabolite was noted in tumors treated with NSC-35843, but no information regarding its identity has been obtained.
If the association of NSC-38280 with the L12l0 and P388 tumors in vivo does not involve a metabolic alteration of the drug, the resistant line may have a mechanism to prevent the phthalanilide from exhibiting a toxic effect on the tumor cells. In this connection, Ll2l0 cells resistant to 8-azaguanine (71) and monkey kidney cells that have become resistant to the cytotoxic effects of 6-mercaptopurine and 2,6-diaminopurine in cell culture (72) are reported to lack some enzymes . essential for conversion of these purine antagonists to their respective cytotoxic nucleotides. The sensitive cells incorporated the fraudulent purines and were inhibited. A similar mechanism may operate with the phthalanilides: The resistant line may lack an enzyme or receptor instrumental in retaining the phthalanilide in the cell at a concentration sufficient to inhibit or kill the cell, and the differences in uptake between sensitive and resistant cells in vivo may reflect this phenomenon. Methylglyoxal bis-guanylhydrazone, dihydrochloride (NSC-32946), which is active against experimental tumors and human acute myelocytic leukemia (13, 74) , behaves like NSC-38280 in several respects. No evidence of metabolites was found in the urine of the animals tested (15) .
Studies of the uptake of NSC-32946 by sensitive and resistant lines of L1210 indicated that about the same amount of drug was taken up by each line during the 1st hour of exposure in vivo, but by 24 hours the resistant cells contained only about onethird as much as the sensitive cells (16) . No metabolite of NSC-32946 was found in normal and L1210 leukemia-bearing mice. These findings led the authors to propose that the resistant tumor is characterized by a diminished capacity to bind the drug and that the permeability to drug has not been altered by the development of resistance.
The relationships existing between phthalanilide accumulation in both the solid subcutaneous and ascites L1210 and the therapeutic effect of NSC-38280 or NSC-35843 are also worthy of comment. Mice bearing the solid tumor succumb to what is essentially a systemic leukemia. 9 However, after a course of delayed therapy with NSC-38280 or NSC-35843, the survival of the mice is increased significantly (29 and 47%, respectively), while the growth of solid tumor is inhibited only to the extent of 14 and 27 percent, respectively, and the concentration of drug equivalents in the solid tumors (sensi tive lines) reaches 17 to 27 and 35 to 41 j.Lg per g of tissue, respectively. The resistant solid tumor does not respond to therapy with either drug, nor do the resistant tumors contain the concentration of drug equivalents found in the sensitive line. That the therapeutic effect of NSC-38280 seems to be primarily on the leukemia is not surprising if one considers that the levels of phthalanilide bound by sensitive ascites cells based on accumulation per g of wet tissue may be 10 to 20 times the levels found in the sensitive solid tumor.
